MAPT and Alzheimer disease: Preclinical validation in transgenic AD murine models demonstrated dose-dependent reductions in both Aβ plaque burden (40% vs. controls) and p-tau levels (Ser396/404 phosphorylation sites), concomitant with Morris water maze performance enhancement [174].